![Nicolas Leupin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nicolas Leupin
No open positions remaining
Net worth: 2 M $ as of 31/07/2026
Profile
Nicolas Leupin worked as Chief Medical Officer at argenx SE from 2016 to 2019 and at Molecular Partners AG from 2019 to 2023.
Also held the position of Chief Medical Officer at NovoCure Ltd. and was a Member of the Swiss Group for Clinical Research.
Education includes a doctorate from the University of Bern and an MBA from Jones International University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NOVOCURE LTD. 0.09% | 06/04/2026 | 102,979 ( 0.09% ) | 2 M $ | 31/07/2026 |
Former positions of Nicolas Leupin
| Companies | Position | End |
|---|---|---|
| MOLECULAR PARTNERS AG | Chief Tech/Sci/R&D Officer | 24/08/2023 |
| ARGENX SE | Chief Tech/Sci/R&D Officer | 01/07/2019 |
| NOVOCURE LIMITED | Chief Tech/Sci/R&D Officer | - |
Swiss Group for Clinical Research | Corporate Officer/Principal | - |
Training of Nicolas Leupin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
28
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Jones International University
 Jones International University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Bern
 University of Bern Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
 Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
NovoCure Ltd.
 NovoCure Ltd. Medical SpecialtiesHealth Technology Operates as a commercial-stage oncology company | Health Technology |
argenx SE
 argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
Swiss Group for Clinical Research |
- Stock Market
- Insiders
- Nicolas Leupin
